Vasopressin (ADH) Research Overview (also known as Arginine Vasopressin, AVP, ADH, Antidiuretic Hormone, 8-Arginine Vasopressin, Pitressin)
Vasopressin (arginine vasopressin, AVP), also known as antidiuretic hormone (ADH), is a neuropeptide synthesized in the hypothalamus and released from the posterior pituitary, playing critical roles in water homeostasis, blood pressure regulation, and complex social and cognitive behaviors. Intranasal vasopressin research has revealed its influence on memory consolidation, social bonding, trust, and stress responses, making it a target of investigation for social cognition enhancement, PTSD, and autism spectrum conditions. Its receptor subtypes (V1a, V1b, V2) mediate distinct physiological effects across peripheral and central nervous systems.
What Is Vasopressin (ADH)?
Vasopressin, formally arginine vasopressin (AVP) and commonly called antidiuretic hormone (ADH), is a cyclic nonapeptide hormone and neuropeptide. Early physiological work in the late nineteenth and early twentieth centuries established that extracts of the posterior pituitary could raise blood pressure and reduce urine output. The antidiuretic principle was subsequently isolated and characterized, and synthetic vasopressin became an important treatment for disorders involving inadequate water conservation. The closely related peptide oxytocin was isolated from the same general line of research. Modern molecular, neuroendocrine, and behavioral studies have expanded the field beyond its classical endocrine functions, showing that vasopressin also acts within the brain to influence stress responsivity, social recognition, territoriality, aggression, pair bonding, and aspects of learning and memory.
Vasopressin has two connected but partly separable biological roles. Peripherally, it is an antidiuretic hormone that promotes water reabsorption in the kidney and, at higher concentrations, a vasopressor that constricts blood vessels and supports arterial pressure. Centrally, it is a neuromodulator released by neuronal circuits in the hypothalamus and other brain regions. The mature human peptide contains nine amino acids and resembles oxytocin in both sequence and three-dimensional structure. The peptides differ at positions 3 and 8: vasopressin contains phenylalanine at position 3 and arginine at position 8, whereas oxytocin contains isoleucine and leucine at those positions. AVP is synthesized mainly in magnocellular and parvocellular neurons of the hypothalamic supraoptic and paraventricular nuclei. Magnocellular axons project to the posterior pituitary, where vasopressin is stored and released into the bloodstream. Other axons release AVP locally within the brain, including projections toward the amygdala, hippocampus, lateral septum, and other limbic and hypothalamic structures. Blood-borne ADH and locally released central AVP should therefore not be treated as interchangeable: peripheral effects are dominated by renal and vascular receptors, whereas social and cognitive effects depend on brain access, receptor distribution, dose, sex, context, and individual biology.
Research Indications
Hemodynamic Support
Vasodilatory septic shock
Continuous low-dose vasopressin has been extensively studied as an adjunct vasopressor in catecholamine-refractory vasodilatory shock, primarily to raise vascular tone and reduce norepinephrine requirements.
V1a receptor-mediated vasoconstriction
Vasopressin activates vascular V1a receptors, increasing intracellular calcium in smooth muscle and producing vasoconstriction through a mechanism distinct from adrenergic pressors.
Water Balance & Endocrine Research
Antidiuretic signaling
Renal V2 receptor activation promotes aquaporin-2 insertion in collecting-duct cells, increasing water reabsorption and urine concentration.
Central diabetes insipidus
Vasopressin replacement historically supported management of central diabetes insipidus, although desmopressin is generally preferred clinically because of greater V2 selectivity and longer action.
Social Cognition & Mood
Social communication
Small human studies of intranasal vasopressin have reported sex-dependent changes in social communication, attention to social cues, and affiliative behavior; findings are heterogeneous and not therapeutic guidance.
Stress and threat processing
Central vasopressin pathways are implicated in hypothalamic-pituitary-adrenal axis regulation, anxiety-like behavior, and salience processing in preclinical and early translational work.
Memory Research
Hippocampal vasopressin signaling
Animal research links vasopressinergic signaling with hippocampal plasticity, social memory, and retrieval processes, but translation to cognitive enhancement in humans remains unestablished.
Sublingual use
Reliable clinical evidence for sublingual vasopressin in cognition or mood is lacking. Peptide absorption, dose delivery, and systemic exposure may be variable with non-parenteral formulations.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Vasodilatory septic shock adjunct | 0.01–0.04 units/min | Continuous, ICU titration | IV infusion |
| Central diabetes insipidus historical replacement | 5–10 units | Every 6–8 hours, individualized | Subcutaneous or IM injection |
| Acute bleeding-variceal protocols | 0.2–0.4 units/min | Short-term monitored infusion | IV infusion |
| Social-cognition experimental studies | No established sublingual dose | Research-only; protocol specific | Sublingual |
Timing
Hemodynamic effects of IV infusion are monitored continuously and may occur rapidly. Antidiuretic effects require serial assessment of urine output, serum sodium, fluid balance, blood pressure, and signs of ischemia. Sublingual cognitive-use timing is not established in clinical literature.
Peptide Interactions
Used together in monitored vasodilatory shock protocols because vasopressin provides non-adrenergic vasoconstriction and may reduce catecholamine dose requirements.
Additive antidiuretic activity can increase water retention and hyponatremia risk. Concurrent use requires clinician-directed sodium and fluid monitoring.
Lithium can impair renal responsiveness to vasopressin and contribute to nephrogenic diabetes insipidus, making water-balance responses less predictable.
Corticosteroids may alter vascular responsiveness and are sometimes co-administered in shock; the combination belongs in monitored acute-care protocols rather than self-directed use.
Tricyclic antidepressants can potentiate vasopressor effects; concurrent use may substantially increase pressor and cardiac risk unless managed by a specialist.
These closely related peptides have partial receptor cross-reactivity. Combined administration may create unpredictable vascular, uterine, and water-balance effects.
Reported Research Timeline
01Minutes after parenteral exposure: vascular tone and blood-pressure effects may emerge rapidly; onset and magnitude depend strongly on route, dose, circulating volume, and concurrent vasopressors.
02Within 1–4 hours (reported in cited studies): reduced urine output and increased urine concentration may occur through V2-mediated water reabsorption; fluid intake and serum sodium materially affect safety.
03Over 6–12 hours: persistent antidiuresis can shift free-water balance. Clinical protocols monitor urine output, electrolytes, blood pressure, peripheral perfusion, and ischemic symptoms.
04Within 24 hours (reported in cited studies): sodium abnormalities, fluid overload, or excessive vasoconstriction may become apparent, particularly with repeated dosing, renal impairment, or concurrent antidiuretic medicines.
05Days to weeks (reported in cited studies): no validated timeline exists for cognitive or mood benefits. Repeated non-clinical use is not supported by established efficacy data and may increase cumulative water-balance and cardiovascular risk.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Vasopressin is a potent prescription vasopressor and antidiuretic hormone, not a routine nootropic or wellness compound; injectable use requires medical supervision.
Water intoxication and hyponatremia are important risks. Avoid excessive fluid intake and do not use without an individualized fluid and electrolyte plan.
Use particular caution with coronary artery disease, peripheral vascular disease, heart failure, arrhythmias, migraine with vascular features, renal impairment, or seizure history.
Blood pressure, heart rate, urine output, body weight, and serum sodium are clinically relevant monitoring parameters during systemic exposure.
Sublingual preparations may have variable peptide stability and absorption; absence of an immediate effect does not establish safety of dose escalation.
Pregnancy, breastfeeding, and pediatric use require specialist oversight because vasopressin can affect uterine and cardiovascular physiology.
Seek Medical Attention If:
Chest pain, severe shortness of breath, fainting, a new irregular heartbeat, or cold/painful/discolored fingers or toes occurs.
Severe headache, confusion, unusual drowsiness, agitation, vomiting, seizure, or sudden weight gain develops, as these may indicate dangerous hyponatremia or water intoxication.
Marked abdominal pain, pallor, sweating, severe hypertension, or a major drop in urine output occurs.
Any suspected dosing error, accidental injection, or use alongside another antidiuretic or potent vasopressor has occurred.
Quality Indicators
Verified Marker
Licensed-source traceability
Prefer product supplied through a licensed pharmacy or documented clinical supply chain, with manufacturer, lot number, expiry date, storage instructions, and concentration clearly stated.
Verified Marker
Intact lyophilized cake or validated solution
For lyophilized material, look for a uniform, dry cake without discoloration, collapse, excess moisture, or particulate contamination. Ready-to-use solutions should be clear and free of visible particles.
Verified Marker
Reconstitution clarity and sterile handling
Reconstituted peptide should dissolve as specified by the manufacturer into a clear solution. Use only validated diluent, aseptic technique, and stated beyond-use conditions.
Acceptable Range
Cold-chain documentation
Verify refrigeration requirements and shipment conditions. A brief, documented excursion may be addressed by manufacturer stability data; undocumented heat exposure should be treated cautiously.
Quality Concern
Unverified research vials or ambiguous labeling
Avoid vials lacking a verifiable lot, concentration, expiry, sterility assurance, or storage history. A generic certificate of analysis does not establish injectable sterility, endotoxin control, or correct identity.
Research Citations
- Vasopressin versus norepinephrine infusion in patients with septic shock
Russell, J. A., Walley, K. R., Singer, J., et al., 2008, New England Journal of Medicine - Vasopressin deficiency contributes to the vasodilation of septic shock
Landry, D. W., Levin, H. R., Gallant, E. M., et al., 1997, Circulation - Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial
Gordon, A. C., Mason, A. J., Thirunavukkarasu, N., et al., 2016, JAMA - Vasopressin modulates human social communication
Thompson, R. R., George, K., Walton, J. C., Orr, S. P., Benson, J., 2006, Proceedings of the National Academy of Sciences of the United States of America - Vasopressin and oxytocin receptor agonists and antagonists as research tools and potential therapeutic agents
Manning, M., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Guillon, G., 2012, Frontiers in Neuroendocrinology
Research Focus
neuropeptide, memory consolidation, social bonding, cognitive enhancement, antidiuretic, intranasal, PTSD, autism spectrum, hypothalamus
Frequently Asked Questions
What should researchers watch for with Vasopressin (ADH)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Vasopressin (ADH)?
Minutes after parenteral exposure: vascular tone and blood-pressure effects may emerge rapidly; onset and magnitude depend strongly on route, dose, circulating volume, and concurrent vasopressors.
How is Vasopressin (ADH) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →